Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
73°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verastem Inc
(NQ:
VSTM
)
2.460
+0.060 (+2.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Verastem Inc
< Previous
1
2
3
4
Next >
Verastem Oncology Appoints Rob Gagnon to Board of Directors
December 15, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 03, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Appoints Anil Kapur to Board of Directors
October 20, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
October 04, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 08, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
June 06, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
May 18, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 09, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
March 28, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
March 28, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
March 24, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers
January 11, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2022
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
January 04, 2022
From
Verastem Oncology
Via
Business Wire
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
November 22, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at the Jefferies London Healthcare Conference
November 11, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
November 04, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Appoints Michelle Robertson to Board of Directors
October 26, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
September 22, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer
September 20, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
September 19, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
September 07, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 02, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021
July 27, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt
July 19, 2021
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2021
From
Verastem Oncology
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.